Windlas Biotech Limited (NSE:WINDLAS)
India · Delayed Price · Currency is INR 786.70
-16.85 (-2.10%)
Jan 23, 2026, 3:29 PM IST
Windlas Biotech Revenue
Windlas Biotech had revenue of 2.22B INR in the quarter ending September 30, 2025, with 18.93% growth. This brings the company's revenue in the last twelve months to 8.30B, up 19.34% year-over-year. In the fiscal year ending March 31, 2025, Windlas Biotech had annual revenue of 7.60B with 20.43% growth.
Revenue (ttm)
8.30B
Revenue Growth
+19.34%
P/S Ratio
1.99
Revenue / Employee
6.17M
Employees
1,346
Market Cap
16.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 7.60B | 1.29B | 20.43% |
| Mar 31, 2024 | 6.31B | 1.18B | 22.97% |
| Mar 31, 2023 | 5.13B | 471.53M | 10.12% |
| Mar 31, 2022 | 4.66B | 383.28M | 8.96% |
| Mar 31, 2021 | 4.28B | 987.50M | 30.03% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 17.25B |
| Innova Captab | 13.63B |
| Solara Active Pharma Sciences | 12.06B |
| Orchid Pharma | 8.21B |
| RPG Life Sciences | 6.66B |
| Ind-Swift Laboratories | 5.72B |
| Sigachi Industries | 5.09B |
| Beta Drugs | 3.86B |